Form 4: Apogee CFO Sells Shares Under 10b5-1 Plan

Apogee Therapeutics' Chief Financial Officer, Jane Henderson, sold 1,500 shares of common stock for $70 per share on November 25, 2025, as part of a pre-arranged trading plan.

Summary

• Jane Henderson, Chief Financial Officer of Apogee Therapeutics, Inc. (APGE), reported a sale of common stock.
• The transaction involved the disposition of 1,500 shares of Apogee Therapeutics common stock.
• The shares were sold at a price of $70 per share.
• The transaction occurred on November 25, 2025.
• Following this transaction, Jane Henderson directly beneficially owns 196,371 shares of common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024.

Sentiment

Score: 5

Explanation: The transaction is a routine insider sale executed under a pre-arranged 10b5-1 trading plan, which typically indicates a non-discretionary event rather than a change in management's outlook on the company. The sale represents a small fraction of the CFO's total holdings.

Positives

• The transaction was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled and non-discretionary sale, which can reduce concerns about opportunistic insider selling.

Negatives

• A sale by a Chief Financial Officer, even if pre-planned, reduces their direct ownership in the company.

Future Outlook

NA

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but mitigated by the 10b5-1 plan. The sale value is relatively small compared to the company's market capitalization.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled sale of a relatively small number of shares by the Chief Financial Officer under a Rule 10b5-1 trading plan. Such transactions are typically non-discretionary and do not usually signal a change in management's confidence or the company's fundamentals. Given the context, this event alone is unlikely to significantly impact the company's valuation or warrant a change in investment strategy. Investors should continue to monitor broader company performance and market conditions.

Keywords

Apogee Therapeutics, APGE, Insider Trading, Form 4, Stock Sale, Chief Financial Officer, Jane Henderson, 10b5-1 Plan, Equity Transaction